Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition (OTCQB: ADIA) announced a strategic partnership between its research arm Adia Labs and AxiaMD on November 10, 2025.
Under the agreement, AxiaMD's nationwide physician-oversight network will offer Adia Labs' regenerative products to clients while Adia's clinics gain AxiaMD's compliance and oversight services across all 50 states, enabling chiropractic clinics to perform advanced regenerative procedures under full physician oversight. The release highlights FDA-compliant stem cell products, a mutual referral model, and prior company momentum including 200%+ Q3 2025 revenue growth and an OTCQB uplisting toward Nasdaq eligibility.
Adia Nutrition (OTCQB: ADIA) summarized 2025 milestones including a confirmed 200%+ Q3 revenue surge quarter-over-quarter with profit margins above 20%, accelerated commercial expansion, and steps toward Nasdaq uplisting. The company said it will file a Form 10 by end of November 2025 (SEC review period ~60 days) and expects Form 10 effectiveness by late January 2026. Other highlights: sales force tripled with four regional divisions, preferred‑vendor access to >4,000 personal injury physicians, progress toward insurer in‑network status, and a divestiture of Biolete Coffee while retaining an 18% equity stake.
Adia Nutrition (OTCQB: ADIA) announced an early release of its Q3 financial results on October 28, 2025, issued weeks ahead of schedule.
The company reported revenue growth of over 200% versus the prior quarter and a net profit margin of greater than 20%. Management said results exceeded prior forecasts and highlighted operational execution, product momentum, and a focus on stakeholder value. The release invites investors and partners to view the full Q3 financial report and contact CEO Larry Powalisz for inquiries or licensing and partnership opportunities.
Adia Nutrition (OTCQB: ADIA) appointed Dr. Evan Thomas, MD, PhD as Independent Medical Director for its medical division, Adia Med, effective October 21, 2025. Dr. Thomas will oversee clinic practices and clinical operations, including finalizing protocols for the Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program pending in-network provider status with major insurers.
Dr. Thomas is chief medical officer at the Renaissance Institute of Precision Oncology & Radiosurgery and has expertise in CNS and functional radiosurgery, SRS/SBRT, clinical trials, and an innovative radiotherapy joint therapy called Joint Glow. The company invites clinic owners and partners to inquire about licensing and integrating Adia Med regenerative therapies.
Adia Nutrition (OTCQB: ADIA) has engaged an independent accounting firm and securities counsel to prepare and file a Form 10 with the U.S. SEC, marking a move from OTC reporting to full SEC reporting.
The company expects to submit the Form 10 by end of November 2025, notes an SEC review/recognition period of 60 days, and anticipates the filing becoming effective by late January 2026. Full reporting will require audited financials, regular disclosures, and enhanced governance and is presented as a step toward meeting Nasdaq listing requirements and attracting institutional and accredited investors.
Adia Nutrition (OTCQB: ADIA) reported preliminary Q3 results for the quarter ended September 30, 2025 showing a revenue increase of more than 100% quarter‑over‑quarter and a profit margin exceeding 20%. Growth was attributed to higher sales of umbilical cord stem cells and exosome therapies across clinical partnerships, direct‑to‑consumer channels, and national expansion. Management described the quarter as a milestone for the company and said full reviewed financial statements will be posted on OTC Markets and filed by on or before November 15, 2025.
Contact and partnership inquiries directed to CEO Larry Powalisz.
Adia Nutrition (OTCQB: ADIA) announced the sale of its Biolete coffee subsidiary to Cement Factory LLC on October 6, 2025, while retaining an 18% ownership stake in Cement Factory.
The move shifts Adia's focus to regenerative medicine: plans include tripling its specialized sales force in 2025, expanding Adia Med clinics, and funding R&D for next‑generation therapies. The company also cited a court‑ordered cancellation of over 25 million improperly issued shares to enhance shareholder value. Proceeds from the sale will support medical expansion; investor updates will follow via SEC filings and corporate announcements.
Adia Nutrition (OTCQB: ADIA) announced a major expansion of its sales operations by tripling its sales force and establishing four specialized teams. The restructuring creates dedicated teams for the East Coast, West Coast, Central U.S., and national/international markets to promote its Adialabs product line.
The company's portfolio includes AdiaVita (100M umbilical cord stem cells and 3T exosomes per dose), AdiaLink (3.5T exosomes per dose), and Glutaryl Transdermal Glutathione Spray. The expansion aims to enhance market reach and accessibility of these regenerative medicine products to healthcare facilities across the U.S. and globally.
Adia Nutrition Inc. (OTCQB: ADIA) has discovered over 20 million potentially improperly issued shares during an internal audit of its historical share structure. The company has initiated legal proceedings to cancel these shares and return them to the treasury. The questionable shares were issued prior to current management and lack proper documentation and regulatory compliance.
CEO Larry Powalisz emphasized the company's commitment to corporate governance and shareholder value. While addressing these historical issues, Adia continues to focus on its core business of advancing stem cell therapies, including treatments for Multiple Sclerosis, orthopedic conditions, chronic pain, and wound repair.
Adia Nutrition Inc. (OTCQB: ADIA) is finalizing in-network provider status with major health insurance companies including Humana, Florida Blue, Cigna, Medicare, and Medicaid. This strategic move aims to expand patient access to the company's regenerative stem cell therapies.
The company has already submitted applications to Humana and Cigna, initiated the process with Florida Blue, and is actively pursuing Medicare and Medicaid access. This development builds upon Adia's recent partnership with the PI Doctors Elite Community, which connects Adia Labs with over 4,000 personal injury physicians nationwide.